Back to Authors

Darby, Heather

Mayo Clinic

WinnMed

Citations 1

Defining the BTK-dependent chromatin-informed gene regulatory network in chronic lymphocytic leukemia
Guo, Qianqian, Darby, Heather, Parikh, Sameer, Kay, Neil, Wang, Zhiquan , Han, Weiguo , Darby, Heather , Sinha, Sutapa , Yu, Chuanhe , Parikh, Sameer, Kay, Neil

No container title available | May 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9485118/v1 Get It

Abstract Bruton tyrosine kinase (BTK) is central to chronic lymphocytic leukemia (CLL) biology, yet the regulatory programs that depend on BTK remain poorly defined. Here, we used acute NX-5948 (Bexobrutideg)-mediated BTK degradation to define BTK-dependent regulatory circuitry in CLL. Integrating early transcriptional and chromatin responses with chromatin-state annotation, target-gene linkage, and transcription factor assignment, we resolved a chromatin-informed framework linking BTK loss to downstream gene-regulatory output. This framework is separated into two directional programs: a dominant BTK-maintained network that collapsed after BTK degradation and a smaller BTK-released network that emerged upon BTK loss. BTK-responsive elements were concentrated in promoter- and enhancer-linked chromatin compartments, consistent with a model in which BTK-dependent transcriptional output is mediated through specific active regulatory elements. Functional validation in a CLL-like cell model provided orthogonal support for the NFAT-linked component of the BTK-maintained regulatory circuitry. BTK-dependent regulon activity was associated with clinical outcome, and projection of bulk-derived programs into longitudinal single-cell RNA-seq resolved malignant CLL cells into distinct regulatory states with maintained-like and released-like features. Together, this work defines BTK-dependent regulatory programs in CLL through a chromatin-informed framework linking BTK activity to gene-regulatory output. These findings lay the foundation for understanding how BTK-dependent circuitry contributes to malignant cell-state diversity, clinical outcome, and remodeling during therapy.